Drugs / SHP655
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03922308 | Oct 2019 → Aug 2021 | acquired thrombotic thrombocytopenic purpura | Shire | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-03-22 | Takeda | Shire receives FDA Fast Track designation for recombinant ADAMTS13 (SHP655) for treatment of hereditary thrombotic thrombocytopenic purpura takeda.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHP655 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03922308 ↗ |
| Route | Intravenous | “IV injection” NCT03922308 ↗ |